Brought to you by:
-
Track your wRVUs, because no one else does it better
If you were in the audience at the 2024 Southern Association for Vascular Surgery (SAVS) annual meeting, you might have been taken aback by the presentation from UT Health San Antonio and the San Antonio VA Medical Center, presented by Luke D. Perry, DO, and co-authored by Alissa Hart, MD, Reshma D. Brahmbhatt, MD, and…
-
American Venous Forum, AVF 2024, branding, disparities, Eastern Vascular Society, EVS 2024, PAD, Venous disease
Service: Giving back
Pioneering American Venous Forum (AVF) and Eastern Vascular Society (EVS) efforts aimed at breaking down barriers to care and educating patients in economically challenged communities on vascular disease have yielded early gains over the first two events staged this year. The vascular surgeons behind these outreach programs—or days of service—tell Vascular Specialist of their plans…
-
carotid endarterectomy, carotid stenting, CMS, Medicare, NESVS 2024, New England Society for Vascular Surgery, TCAR, textbook outcome
Novel measure suggests 20% of elective carotid revascularizations fail to achieve a textbook outcome
One in five patients failed to achieve a textbook outcome after undergoing carotid endarterectomy (CEA), transcarotid artery revascularization (TCAR) or transfemoral carotid artery stenting (TF-CAS), a Vascular Quality Initiative (VQI) analysis that tested a novel, patient-centric textbook outcome metric found. “Having a non-textbook outcome was prognostic of an inferior five-year survival” among asymptomatic carotid stenosis…
-
arteriovenous fistula, arteriovenous graft, Dialysis access, Merit Medical, VEITH 2024, WAVE trial, Wrapsody
WAVE trial AVG cohort also benefits at six months with Wrapsody
Newly released six-month results from single-arm arteriovenous graft (AVG) cohort in the WAVE (Wrapsody arteriovenous access efficacy) trial showed target lesion and access circuit primary patency rates of nearly 82% and 68.8%, respectively. The latest data on the Wrapsody cell-permeable endoprothesis (Merit Medical) for treatment of stenosis or occlusion within the dialysis access outflow circuit…
-
BEST-CLI: Trial results endure in analysis of patients who presented with diabetes
Diabetes affects approximately 70% of patients with chronic limb-threatening ischemia (CLTI) and is associated with more severe presentation, driven mostly by higher rates of wounds and infections, according to a recently presented retrospective analysis of BEST-CLI randomized controlled trial data. Investigators further found that CLTI patients without diabetes presented with more severe ischemia, were more…
-
AAA, Aortic Research Consortium, BEVAR, F-BEVAR, FEVAR, NESVS 2024, New England Society for Vascular Surgery
Rates of MAE and reintervention following F/BEVAR remain ‘stable,’ Aortic Research Consortium data show
Latest study out of consortium details trends and outcomes after F/BEVAR procedures carried out over an eight-year period under consortium of 10 physician-sponsored IDEs. Despite increasing repair extent and complexity, rates of technical failure, adverse events and reintervention remained “stable” following fenestrated and branched endovascular aneurysm repair (F/BEVAR) for abdominal aortic aneurysms (AAAs), a newly…
-
One-year data from VenoValve US pivotal trial emerges
Envveno Medical has announced that it will present one-year data on all patients from the VenoValve US pivotal trial today at the VEITHsymposium (19–23 November, New York, USA). The definitive one-year data support the application submitted earlier this week by Envveno Medical seeking premarket authorisation (PMA) from the US Food and Drug Administration (FDA) to market and sell…
-
PMA application submitted for VenoValve device
enVVeno Medical today announced it has submitted an application with the U.S. Food and Drug Administration (FDA) seeking approval to market the VenoValve—a surgical venous valve implant for chronic venous insufficiency—in the USA. Definitive one year data from the application are to be presented on Wednesday at the 51st Annual VEITHsymposium in New York City…
-
Research suggests arm vein is the best alternative bypass conduit to GSV in patients with CLTI
A new analysis has found arm vein to be the most suitable alternative conduit to great saphenous vein (GSV) in chronic limb-threatening ischemia (CLTI) patients, particularly in below-knee bypass targets. Prosthetic grafts also represent an adequate option, the researchers add, whilst advising that the use of biological grafts in this setting should be limited. The…
-
American Venous Forum, Eastern Vascular Society, EVS, Midwestern Vascular Surgical Society, MVSS, PAD, Western Vascular Society, WVS
Regional societies see presidential changing of the guards
Brajesh K. Lal, MD, assumed the Eastern Vascular Society (EVS) presidency during the 2024 EVS annual meeting. He took over from Kathleen Ozsvath, MD. Patrick Muck, MD, assumed the reins of the Midwestern Vascular Surgical Society (MVSS) at the conclusion of the 2024 MVSS annual meeting, succeeding Bernadette Aulivola, MD,. Ahmed Abou-Zamzam Jr., MD, has…